01At a glance
02What it is
Alpha-1 antitrypsin deficiency is an autosomal co-dominant disorder caused by the SERPINA1 Z allele, whose protein product polymerizes and accumulates in the liver (causing cirrhosis) while deficient circulating antiprotease leaves the lungs vulnerable to emphysema. It is a dual gain-of-function (liver) and loss-of-function (lung) disease; augmentation therapy treats the lung component.
03What goes wrong
Dual mechanism. (1) Gain-of-function in the liver: the Z-variant alpha-1-antitrypsin misfolds and polymerizes, accumulating in hepatocyte endoplasmic reticulum, causing liver injury, fibrosis, and cirrhosis. (2) Loss-of-function in the lung: reduced circulating A1AT (a serine protease inhibitor) leaves the lung unprotected from neutrophil elastase, causing early-onset emphysema. The liver toxicity is the toxic-gain-of-function component.
04How NIGHTINGALE routes it
Recommended modality: augmentation (LoF) + polymer blocker/degrader (GoF, investigational)
COMPLEX — NOT a blanket 'eligible'. The liver disease is a toxic gain-of-function (Z-AAT polymerization), so a selective degrader of polymerized Z-AAT is mechanistically plausible for the HEPATIC component. However the lung disease is loss-of-function (deficient antiprotease), where degradation would worsen it. AUTOTAC is NOT appropriate for the disease as a whole — only a targeted hepatic strategy would qualify. The approved therapy is augmentation (restore the missing antiprotease), which addresses the LoF component.
05Treatment today
Alpha-1 Proteinase Inhibitor (human, e.g. Prolastin-C / Zemaira / Aralast)
1987 (first A1AT augmentation products)Intravenous infusion of purified human alpha-1-antitrypsin to restore circulating antiprotease levels, protecting the lung from elastase-mediated damage. Addresses the loss-of-function component only; does not clear hepatic Z-AAT polymers.
06In the pipeline
- Small-molecule polymerisation blockers (e.g. targeting the Z-AAT polymer interface — JCI Insight 2025)
- Selective degraders of polymerized Z-AAT (autophagy enhancers / PROTAC) — preclinical, for the hepatic component
- siRNA silencing of SERPINA1 (e.g. fazirsiran/ARO-AAT — clinical)
- Gene therapy / CRISPR correction (preclinical)
Key reference: PMID 32268028 · PubMed
07Verification
Every line below is the registry's own verification record — what was checked, against which source, and what is still open.
- uniprot: P01009 = SERPINA1 (Alpha-1-antitrypsin), 418 aa — VERIFIED via UniProt REST API (live)
- gene mutation: SERPINA1 Z allele (Glu342Lys / PI*Z) — VERIFIED (OMIM 613490; literature)
- inheritance: Autosomal co-dominant — VERIFIED (OMIM 613490; Orphanet)
- orpha code: 60 = Alpha-1-antitrypsin deficiency (Active) — VERIFIED via Orphanet API (live, 2026-07-02)
- drug mw: A1AT augmentation is a plasma-derived protein (~52 kDa), not a small molecule — MW/CID NOT APPLICABLE (left 0, not fabricated)
- fda date: A1AT augmentation products 1987 — commonly cited; exact NDA not re-verified this session
08Sources
| Fact | Source | Accession | Retrieved |
|---|---|---|---|
| Gene/protein identity | UniProt | P01009 (SERPINA1, Alpha-1-antitrypsin, 418 aa) | 2026-10-04 |
| Disease classification & definition | Orphanet | ORPHAcode 60 (Alpha-1-antitrypsin deficiency) | 2026-10-04 |
| Inheritance & genetics | OMIM | 613490 (Alpha-1-antitrypsin deficiency) | 2026-10-04 |
| Z-AAT polymerisation (gain-of-function) mechanism | JCI Insight 2025 | Ronzoni et al., polymer-blocking therapy (10.1172/jci.insight.194354) | 2026-10-04 |
Corrections carried into registry v2 (3)
- VERIFIED (2026-10-04): built fresh. ORPHAcode 60 confirmed live via Orphanet API.
- CLARIFIED: A1AT deficiency is a DUAL-mechanism disease — liver (toxic GoF polymerisation) + lung (LoF antiprotease deficiency). AUTOTAC is NOT a blanket 'eligible' — only the hepatic component is a plausible degrader target.
- CLARIFIED: augmentation therapy addresses the LoF (lung) component only; it does not clear hepatic Z-AAT polymers.